Houston named the No.1 emerging city for biopharma in inaugural report
Biopharma Leader
Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).
The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.
Here’s how Houston ranked in the report’s different categories;
- No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
- No. 2 for emerging regions for jobs, with 28,000 jobs
- No. 2 for lab space, with roughly 8 million square feet in the market
- No. 6 for patents, with 2,760 patent families
According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.
The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.
Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.
The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.
“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”
The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.
Other cities to make the list include:
- No. 2 Minneapolis-St. Paul
- No. 3 Denver-Boulder
- No. 4 St. Louis
- No. 5 Dallas-Fort Worth
States to make the list include:
- No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
- No. 2 Indiana (including Indianapolis)
- No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
- No. 4 Georgia (including Atlanta and Augusta)
- No. 5 Wisconsin (including Madison and Kenosha)
Regional state clusters to watch include:
- Phoenix
- Pittsburgh
- Greater Richmond, Virginia
- South Carolina
- Utah
See the full report here.
- 2 Houston high schools soar as America's best for 2026, says U.S. News ›
- New report ranks Houston as America's No. 2 least safe city ›
- Houston VC funding nears $1B in first half of 2026, report says ›
- Report: Houston reclaims top 10 ranking among America's best cities ›
- Houston helps power Texas’ rise as AI infrastructure hub, new report finds ›
